Recent Articles from GlobeNewswire

Partnership with abc Co., Ltd. and ReYuu Japan to to Support Localized Dogecoin Use Cases

Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today outlined 2026 as a program-defining year for allogeneic CAR T, with multiple first-half clinical readouts expected to test, and potentially validate, whether off-the-shelf CAR T can be delivered at biologic-like scale, in real-world settings, across oncology and autoimmune disease.

LAS VEGAS, Jan. 08, 2026 (GLOBE NEWSWIRE) -- TON Strategy Company (Nasdaq: TONX), a digital asset treasury company dedicated to holding Toncoin ($TON), today announced the appointments of Mary L. Marbach as General Counsel and Corporate Secretary and Bill J. Rivard as Chief Accounting Officer, effective January 5, 2026.

TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has executed an agreement with Østfold Hospital Trust of Norway.

PLANTATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alliance Entertainment Holding Corporation (NASDAQ: AENT), the world’s largest distributor of vinyl records and a leading curator of physical entertainment products and collectibles, today announced the appointment of Jeffrey Smith as Senior Vice President of Sales and Marketing for Alliance Authentic™, the company’s newly launched premium platform for authenticated, numbered, investment-grade vinyl collectibles.

CULVER CITY, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, will be participating in the 2026 ICR Conference from January 12-14, 2026, at the Grande Lakes Resort in Orlando, Florida.

Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027

- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 –

BOCA RATON, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (the “Company” or “NewtekOne”) (NASDAQ: NEWT) has posted to the Investor Relations section of its website (link) an investor presentation for its previously announced “2026 Analyst and Investor Day” event to be held on January 8, 2026 at 12:00 PM. In addition to hosting investors and analysts in person at the Company’s Boca Raton headquarters, the event is being webcasted live. To access the live webcast, participants should register online at NewtekOne 2026 Investor Day. A replay of the event will be available on NewtekOne’s website shortly after the live event and will be available for a period of 90 days.

World’s Largest Accelerator for Optics, Photonics, and Imaging (OPI) Offers $100K Immediate Funding and Strategic Access to the "Optics Capital of the World"

CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that Michel Dahan, President and Chief Executive Officer, is scheduled to present during the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.

LAS VEGAS, Jan. 08, 2026 (GLOBE NEWSWIRE) -- DDPAI, a global innovator in smart dashcam technology, officially made its North American debut at CES 2026, marking a key milestone in the brand’s global expansion. Under the theme “Beyond Dashcams, Enrich Car Lifestyle,” DDPAI presents its vision of redefining dashcams—not just as recording tools, but as intelligent companions that enhance safety, convenience, and everyday car-related experiences.

Contract expansion reflects nearly four-year relationship supporting large-scale cloud security and compliance operations

Follow‑On Update Builds on Recently Announced National Retail Pilot and Enterprise Deployment Partnership

State of Crypto Perpetual Swaps 2025 details market stress, trust gaps and new derivatives trends

CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that Doug Manion, M.D., FRCP (C), Chief Executive Officer and Board Member, will present a company overview at the upcoming 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 8:00 a.m. PT in San Francisco, CA.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today provided business updates and outlined anticipated growth drivers for 2026, including progress across its commercial programs and clinical development initiatives.

Review of 2025 exploration activities and planned technical priorities across the Tharsis and Big Mack projects

Nissan is the first automaker to join the CCC® OEM Link Network to streamline their certification process and improve performance visibility, supporting quality repairs

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care

SCOTCH PLAINS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Navigator Medicines Inc., a clinical-stage biotech company pioneering best-in-class bispecific antibodies (bsAb) for inflammatory disorders and autoimmune diseases in areas of high unmet need, today announced significant progress across its innovative anti-OX40L and anti-TNF combination pipeline, marking the Company's transition to a clinical focused organization with two investigational medicines in active clinical development.

LOS ANGELES, Jan. 08, 2026 (GLOBE NEWSWIRE) -- LiveOne (Nasdaq: LVO), an award-winning, creator-first music, entertainment, and technology platform, today announced major financial and strategic milestones.

LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Diginex Limited (NASDAQ: DGNX), (“Diginex” or the “Company”), a leading provider of Sustainability RegTech solutions, today announced the successful closing of its acquisition of The Remedy Project Limited ("The Remedy Project"), a Hong Kong based advisory and research organization specializing in labor and human rights in global supply chains, with recognized expertise in human rights due diligence, grievance mechanisms, and remediation. As consideration for the acquisition Diginex issued the sole shareholder of The Remedy Project 1,000,000 shares of Diginex ordinary shares and committed to issue up to an additional 1,000,000 shares of Diginex ordinary shares, provided certain operating and earnout targets are met over the next three years. This strategic move combines Diginex's advanced supply chain technology with The Remedy Project's deep expertise in operational-level grievance mechanisms and worker rights, creating a comprehensive ecosystem for businesses to achieve resilient, ethical operations.

PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced it has entered into a securities purchase agreement for a private placement for initial gross proceeds of approximately $135 million to the Company, before placement agent fees and offering expenses.

Monthly release covers the period from December 1-31, 2025

CARMEL, Ind., Jan. 08, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that the Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) is now in effect, completing a successful commercial milestone for the Company.

New collaboration combines G Squared’s dedicated secondary capital with NPM’s liquidity execution platform to help private companies design and deliver secondary liquidity when they need it most

Expert stakeholders establish use cases, minimum acceptable performance standards, and ideal test characteristics to support early detection, diagnosis, and characterization of cognitive impairment

Program kickoff marks critical step in the commercial deployment of AirJoule™ water-from-air systems for data center applications

~Company Set to Deliver Record 2025, Continues Recurring Revenue Transition~

Boothwyn, PA., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pentec Health, Inc. (Pentec) today announced the acquisition of Hartley Medical Center Pharmacy, LLC (Hartley Medical), a nationally recognized compounding pharmacy focused on the sterile compounding of intrathecal (IT) medications used to treat chronic pain and spasticity. Hartley Medical will continue operating from its Long Beach, California 503A pharmacy. Founding member and owner William Stuart will remain with the organization as General Manager.

Agreement Supports Continuous, High-Revisit Monitoring at Scale

Vancouver, BC, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (“Skyharbour” or the “Company”), is pleased to announce that it has acquired by low-cost staking forty new prospective uranium exploration claims in Northern Saskatchewan, increasing Skyharbour’s total land package that it has ownership interest in to 662,887 hectares (1,638,029 acres) across 43 projects. The newly staked claims, which are 100% owned by the Company, add 64,913 hectares (160,403 acres) to Skyharbour’s existing holdings in and around the Athabasca Basin, home to the highest-grade uranium deposits in the world and consistently ranked as a top global mining jurisdiction by the Fraser Institute. While Skyharbour remains focused on advancing its co-flagship Russell Lake project portfolio, recently joint-ventured with Denison Mines, and its 100% owned Moore Project, these new claims will form part of the Company’s prospect generator business through which Skyharbour will seek strategic partners to advance and unlock value from these assets.

First year of CRC’s “Football Without the Footprint” delivers measurable emissions reduction and local community impact

GAITHERSBURG, Md. and PARIS and ADDIS ABABA, Ethiopia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced a collaboration agreement with PANTHER to provide additional financial support to continue progressing the Africa CDC-led ‘MpOx Study in Africa’ (MOSA). This initiative aims to advance research into effective treatments for patients diagnosed with mpox, a virus for which there is currently no dedicated antiviral therapy. Launched in 2024, MOSA is a double-blind, platform-adaptive clinical trial designed to evaluate potential treatment options for mpox across multiple African countries. The study initially received funding from the European Union and Africa CDC.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced encouraging initial safety and PK data from the first cohort of healthy volunteers in its ongoing Phase 1 trial of AX-0810 and provided an update on broader pipeline progress and anticipated 2026 milestones.

Early Access Program participants receive exclusive use of Nautilus’ Iterative Mapping method, initially through a validated tau proteoforms assay, with the potential to accelerate Alzheimer’s and neurodegenerative disease research

MANCHESTER, N.H., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Allegro MicroSystems, Inc. (Nasdaq: ALGM) today announced it plans to release financial results for its third quarter fiscal year 2026 prior to the market open on Thursday, January 29, 2026. Following the press release, Mike Doogue, President and Chief Executive Officer, and Derek D’Antilio, Executive Vice President and Chief Financial Officer, will host a conference call at 8:30 a.m. Eastern Time to discuss the Company’s results and business outlook.

FORT WORTH, Texas, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vickery Energy Partners, LLC (“Vickery”), a portfolio company of Quantum Capital Group, announced today that it has closed on the acquisition of Tribune Resources, LLC from Tribune Resources, Inc (“Tribune”). The transaction includes assets located primarily in Wetzel, Tyler, Harrison and Doddridge counties, West Virginia, spanning a total of approximately 38,000 net acres with more than 200 million cubic feet equivalent per day (MMcfe/d) of net production.

Industry Leader Poised to Become First FedRAMP-Authorized AI Observability Platform

ROSCREA, Ireland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited ("Renexxion"), a private biopharmaceutical company focused on advancing new therapies for patients with significant unmet needs in gastrointestinal ("GI") disorders, announced that the United States Patent and Trademark Office ("USPTO") has granted its sixth U.S. patent for naronapride. The patent (Patent No. 12,391,684) encompasses pharmaceutical composition having a trihydrate form of naronapride and related dosage forms and methods of use for treating a range of GI disorders.

Phare Audit Uses Proprietary Agentic AI to Maximize Earned Reimbursement, Enhancing R1’s Industry-Leading DRG-V with Full Auditability

Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance

The New EveryDollar Introduces Personalized Plans, Live Coaching and a Margin-Finding Tool to Help Users Beat Debt, Give Generously and Build Lasting Wealth

SANTA CLARA, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- SiTime Corporation (Nasdaq: SITM), the Precision Timing company, today announced that SiTime’s chief executive officer, Rajesh Vashist, will participate at the 28th Annual Needham Growth Conference to be held at the Lotte New York Palace Hotel. SiTime management is scheduled to host a fireside chat on Tuesday, January 13, 2026 at 2:15 p.m. EST and will be available to meet with attending investors throughout the day.

KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ: ALPS) (the “Company” or “Alps Group”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026.

SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Meltwater, a global leader in media, social, and consumer intelligence, has achieved SOC 2 Type II certification, underscoring the company's commitment to maintaining the highest standards for data security.

SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced the expansion of its Scientific Advisory Board (SAB) to include three additional key opinion leaders: James Krueger, M.D., Ph.D., from The Rockefeller University; Iain McInnes, C.B.E., Ph.D., F.R.C.P., F.R.S.E., F.Med.Sci., from the University of Glasgow; and John O’Shea, M.D., from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). As an employee of the United States Government and National Institutes of Health, Dr. O’Shea will serve as an SAB member under an official duty authorization (ODA) to provide public benefit by facilitating the development of drugs to treat autoimmune and inflammatory diseases.

SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- LPL Financial LLC announced today that financial advisors Spencer W. Rand, CFP® and Michael J. Williams, CFP® of Rand, Williams & Associates, LLC have joined LPL Financial’s broker-dealer and Registered Investment Advisor (RIA) platform. They reported serving approximately $260 million in advisory, brokerage and retirement plan assets* and join LPL from Osaic.

– Product Revenues, Net Expected in the Range of $805 Million to $825 Million –

Newly Appointed Board and Advisory Leaders Add Diverse Perspectives and Strategic Experience to Propel the Organization’s Mission Forward

PHILADELPHIA and COPENHAGEN, Denmark, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, today announced its launch with a $159.8 million Series A financing. Proceeds from the financing will support Phase 2 clinical development of ALV-100, the company’s lead program, and Investigational New Drug (IND) filings of several early proprietary development candidates, including its highly selective Amylin peptide agonist.

– Achieved 98% manufacturing batch success rate at BaseCamp across cell therapy, viral vector, and mRNA

Dr. Theodosios Bisdas is a renowned vascular surgeon and Head of Clinic of Vascular Surgery at the Athens Medical Center

Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12th, 2026, at 4:30 p.m. PST (7:30 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the company’s website (www.enovis.com) at Events and Presentations.      

Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028

Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy*

BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will present at the 44th Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12-15, 2026. The management team will also participate in one-on-one investor meetings.

WASHINGTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Joshua Baca as a Senior Managing Director.

Company exits 2025 debt-free after repaying credit facility, underscoring balance sheet strength

Tenth Issued Patent for the ZIP™ Implant Family

HHH to Host Earnings Call on February 20, 2026

New research analyzing teacher-designed SchoolAI ‘Spaces’ shows AI is most often used to promote reasoning, analysis, and evaluation rather than answer-getting

NEW HAVEN, Conn., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced preliminary fourth quarter (Q4) revenue and recent business highlights.

RICHMOND, Va., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) (“Indivior PLC” or the “Company”) today announced its full-year 2026 financial guidance.

Initial study will enable further collaboration on the predictive capabilities of StemPrintER

State of Crypto Perpetual Swaps 2025 details market stress, trust gaps and new derivatives trends

CMR Surgical receives CE Mark for use of Versius in paediatric surgery

BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that Stephen (Steve) Griffin, current Executive Vice President, Chief Financial Officer and Chief Operating Officer, has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective February 1, 2026. Mr. Griffin will succeed Cheryl R. Blanchard, Ph.D., who will become Executive Chair of the Board of Directors. In addition, John (Jack) B. Henneman, III, Director since 2020, has been appointed Lead Independent Director.

Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data

Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026

-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 –